Role of Aldosterone Blockade for Treatment of Heart Failure and Post-Acute Myocardial Infarction

American Journal of Cardiology

Volumn 97, Issue 10 SUPPL. 1, 2006, Pages 34-40

  Greenberg, Barry ^a   Zannad, Faiez ^b   Pitt, Bertram ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Ctr Hospitalier Univ de Nancy   (France)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; NITRATE; SPIRONOLACTONE;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DEFIBRILLATOR; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; HYPOTENSION; MEDICAL RESEARCH; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVASCULARIZATION; SURVIVAL;

EID: 33646352471     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.03.009     Document Type: Article

References (37)

1. Hasdai D., Topol E.J., Kilaru R., Battler A., Harrington R.A., Vahanian A., Ohman E.M., Granger C.B., Van de Werf F., Simoons M.L., O'Connor C.M., and Holmes Jr. D.R. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction. lessons from 4 international fibrinolytic therapy trials. Am Heart J 145 (2003) 73-79
2. Steg P.G., Dabbous O.H., Feldman L.J., Cohen-Solal A., Aumont M.C., Lopez-Sendon J., Budaj A., Goldberg R.J., Klein W., Anderson Jr. F.A., and Global Registry of Acute Coronary Events Investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes. observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 109 (2004) 494-499
3. Wu A.H., Parsons L., Every N.R., Bates E.R., and Second National Registry of Myocardial Infarction. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction. a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 40 (2002) 1389-1394
4. Kober L., Torp-Pedersen C., Pedersen O.D., Hoiberg S., and Camm A.J. Importance of congestive heart failure and interaction of congestive heart failure and left ventricular systolic function on prognosis in patients with acute myocardial infarction. Am J Cardiol 78 (1996) 1124-1128
5. American Heart Association. Heart Disease and Stroke Statistics-2005 Update (2005), American Heart Association, Dallas, TX
6. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., and Gatlin M. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
7. Hayashi M., Tsutamoto T., Wada A., Tsutsui T., Ishii C., Ohno K., Fujii M., Taniguchi A., Hamatani T., Nozato Y., et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107 (2003) 2559-2565
8. Voors A.A., de Kam P.J., van den Berg M.P., et al. Acute administration of angiotensin converting enzyme inhibitors in thrombolyzed myocardial infarction patients is associated with a decreased incidence of heart failure, but an increased re-infarction risk. Cardiovasc Drugs Ther 19 (2005) 119-124
9. Yerkey M., Harjai K., Boura J., Kemis S.J., Dukkipati S., Marsalese D.L., and Walsh D. Early hemodynamic compromise following uncomplicated primary angioplasty for acute myocardial infarction. Circulation 106 (2003) II-363 Abstract 1807
10. Pitt B. Angiotensin converting enzyme inhibitors. should they be used early post myocardial infarction?. Cardiovasc Drugs Ther 19 (2005) 103-104
11. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J., and Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
12. Fonarow G.C., Adams Jr. K.F., Abraham W.T., Yancy C.W., Boscardin W.J., ADHERE Scientific Advisory Committee, Study Group, and and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure. classification and regression tree analysis. JAMA 293 (2005) 572-580
13. Mottram P.M., Haluska B., Leano R., Cowley D., Stowasser M., and Marwick T.H. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110 (2004) 558-565
14. National Heart, Lung, and Blood Institute. Selected NHLBI clinical trials across the U.S. Last update: January 1, 2004. Available at: http://apps.nhlbi.nih.gov/clinicaltrials/Contacts.ASP?TrialNumber=160. Accessed March 21, 2005.
15. van Veldhuisen D.J., Aschermann M., Zannad F., Krum H., Vincent J., Mukherjee R., Pitt B., and EPHESUS Investigators. Eplerenone benefit at 30 days in high-risk subgroups in the EPHESUS trial. Eur J Heart Fail. 4 suppl 1 (2005) 79 Abstract 353
16. Pitt B., Gheorghiade M., Zannad F., Anderson J., van Veldhuisen D.J., Parkhomenko A., Corbalan R., Klug E.Q., Mukherjee R., Solomon H., and EPHESUS Investigators. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction ≤30%. Eur J Heart Fail (2006) Feb 24 e pub
17. Solomon S.D., Zelenkofske S., McMurray J.J.V., Finn P.V., Valezquez E., Ertl G., Harsanyi A., Rouleau J.L., Maggioni A., Kober K., et al., Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352 (2005) 2581-2588
18. Hohnloser S.H., Kuck K.H., Dorian P., Roberts R.S., Hampton J.R., Hatala R., Fain E., Gent M., Connolly S.J., and DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
19. Hartmann R.W., Muller U., and Ehmer P.B. Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis. Eur J Med Chem 38 (2003) 363-366
20. Ulmschneider S., Muller-Vieira U., Klein C.D., Antes I., Lengauer T., and Hartmann R.W. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives. potent and selective inhibitors of aldosterone synthase. J Med Chem 48 (2005) 1563-1575
21. Hayashi M., Tsutamoto T., Wada A., Maeda K., Mabuchi N., Tsutsui T., Matsui T., Fujii M., Matsumoto T., Yamamoto T., Horie H., Ohnishi M., and Kinoshita M. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction. extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 38 (2001) 1375-1382
22. Pacher R., Stanek B., Hulsmann M., Koller-Strametz J., Berger R., Schuller M., Hartter E., Ogris E., Frey B., Heinz G., and Maurer G. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 27 (1996) 633-641
23. Otterstad J.E., St John Sutton M.G., Froeland G.S., Holme I., Skjaerpe T., and Hall C. Prognostic value of two-dimensional echocardiography and N-terminal proatrial natriuretic peptide following an acute myocardial infarction. assessment of baseline values (2-7 days) and changes at 3 months in patients with a preserved systolic function. Eur Heart J 23 (2002) 1011-1020
24. Kapoun A.M., Liang F., O'Young G., Damm D.L., Quon D., White R.T., Munson K., Lam A., Schreiner G.F., and Protter A.A. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-β in primary human cardiac fibroblasts. fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 94 (2004) 453-461
25. Lee C.R., Watkins M.L., Patterson J.H., Gattis W., O'Connor C.M., Gheorghiade M., and Adams Jr. K.F. Vasopressin. a new target for the treatment of heart failure. Am Heart J 146 (2003) 9-18
26. Singh K., Sirokman G., Communal C., Robinson K.G., Conrad C.H., Brooks W.W., Bing O.H., and Colucci W.S. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension 33 (1999) 663-670
27. Tamura A., Shingai M., Aso N., Hazuku T., and Nasu M. Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction. Circ J 67 (2003) 742-744
28. Ohtsuka T., Hamada M., Inoue K., Ohshima K., Sujzuki J., Matsunaka T., Ogimoto A., Hara Y., Shigematsu Y., and Higaki J. Relation of circulating interleukin-6 to left ventricular remodeling in patients with reperfused anterior myocardial infarction. Clin Cardiol 27 (2004) 417-420
29. Puhakka M., Magga J., Hietakorpi S., Penttila I., Uusimaa P., Risteli J., and Peuhkurinen K. Interleukin-6 and tumor necrosis factor α in relation to myocardial infarct size and collagen formation. J Card Fail 9 (2003) 325-332
30. Takahashi T., Anzai T., Yoshikawa T., Maekawa Y., Asakura Y., Satoh T., Mitamura H., and Ogawa S. Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction-role of neurohormones and cytokines. Int J Cardiol 88 (2003) 257-265
31. Uehara K., Nomura M., Ozaki Y., Fujinaga H., Ikefuji H., Kimura M., Chikamori K., Nakaya Y., and Ito S. High-sensitivity C-reactive protein and left ventricular remodeling in patients with acute myocardial infarction. Heart Vessels 18 (2003) 67-74
32. Schwartzkopff B., Fassbach M., Pelzer B., Brehm M., and Strauer B.E. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4 (2002) 439-444
33. Sakai S., Miyauchi T., Kobayashi M., Yamaguchi I., Goto K., and Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384 (1996) 353-355
34. Zannad F., Ketelslegers J.M., Schiffrin E.L., Williams G., and Garthwaite S. The effect of eplerenone on markers of cardiac fibrosis. insights from EPHESUS. [abstract]. J Am Coll Cardiol 43 suppl A (2004) 200A
35. Ketelslegers J.M., Zannad F., Schiffrin E., Chu T.C., Garthwaite S., Patni R., and Pitt B. The effect of eplerenone on the cytokine osteopontin in post-AMI heart failure. an EPHESUS substudy. Eur Heart J 25 suppl (2004) P2912 page 485
36. Trueblood N.A., Xie Z., Communal C., Sam F., Ngoy S., Liaw L., Jenkins A.W., Wang J., Sawyer D.B., Bing O.H., et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 88 (2001) 1080-1087
37. Zohar R., Zhu B., Liu P., Sodek J., and McCulloch C.A. Increased cell death in osteopontin-deficient cardiac fibroblasts occurs by a caspase 3-independent pathway. Am J Physiol Heart Circ Physiol 287 (2004) H1730-H1739